Human Immunodeficiency Virus Type 1 Pol Gene Mutations Which Cause Decreased Susceptibility to 2',3'-dideoxycytidine

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1992 Jan 1

PMID 1317143

Citations 65

Authors

J E Fitzgibbon

R M Howell

C A Haberzettl

S J Sperber

D J Gocke

D T DUBIN

Affiliations

Soon will be listed here.

Abstract

To investigate whether human immunodeficiency virus type 1 pol gene mutations are selected during prolonged 2',3'-dideoxycytidine (ddC) therapy, we used the polymerase chain reaction to amplify a portion of the reverse transcriptase segment of the pol gene from the peripheral blood mononuclear cell DNA of a patient with AIDS before and after an 80-week course of ddC therapy. The consensus sequence from the second sample contained a unique double mutation (ACT to GAT) in the codon for reverse transcriptase amino acid 69, causing substitution of aspartic acid (Asp) for the wild-type threonine (Thr). A mutation (ACA to ATA) also occurred in the codon for position 165, causing substitution of isoleucine (Ile) for Thr. The GAT (Asp) codon was introduced into the pol gene of a molecular clone of human immunodeficiency virus via site-directed mutagenesis. Following transfection, mutant and wild-type viruses were tested for susceptibility to ddC by a plaque reduction assay. The mutant virus was fivefold less susceptible to ddC than the wild type; cross-resistance to 3'-azido-3'-deoxythymidine or 2'3'-dideoxyinosine was not found. The Ile-165 mutation did not confer additional ddC resistance. The Asp-69 substitution may have contributed to the generation of resistant virus in this patient.

Citing Articles

Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibility.

Melikian G, Rhee S, Taylor J, Fessel W, Kaufman D, Towner W Antimicrob Agents Chemother. 2012; 56(5):2305-13.

PMID: 22330916 PMC: 3346663. DOI: 10.1128/AAC.05487-11.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer R, Dupnik K, Winters M, Eshleman S HIV Seq Compend. 2012; 2001:1-51.

PMID: 22324021 PMC: 3274565.

The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Shafer R, Kantor R, Gonzales M AIDS Rev. 2011; 2(4):211-228.

PMID: 19096725 PMC: 2604813.

HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Shafer R, Schapiro J AIDS Rev. 2008; 10(2):67-84.

PMID: 18615118 PMC: 2547476.

Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Zhang Z, Walker M, Xu W, Shim J, Girardet J, Hamatake R Antimicrob Agents Chemother. 2006; 50(8):2772-81.

PMID: 16870771 PMC: 1538665. DOI: 10.1128/AAC.00127-06.

References

St Clair M, Martin J, Tudor-Williams G, Bach M, Vavro C, King D . Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991; 253(5027):1557-9. DOI: 10.1126/science.1716788. View

Nara P, Hatch W, Dunlop N, Robey W, Arthur L, Gonda M . Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. AIDS Res Hum Retroviruses. 1987; 3(3):283-302. DOI: 10.1089/aid.1987.3.283. View

Lopez-Galindez C, Rojas J, Najera R, Richman D, Perucho M . Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method. Proc Natl Acad Sci U S A. 1991; 88(10):4280-4. PMC: 51642. DOI: 10.1073/pnas.88.10.4280. View

Fitzgibbon J, Howell R, Schwartzer T, Gocke D, DUBIN D . In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy. AIDS Res Hum Retroviruses. 1991; 7(3):265-9. DOI: 10.1089/aid.1991.7.265. View

Larder B, Chesebro B, Richman D . Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990; 34(3):436-41. PMC: 171611. DOI: 10.1128/AAC.34.3.436. View

Saiki R, Gelfand D, Stoffel S, Scharf S, Higuchi R, Horn G . Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988; 239(4839):487-91. DOI: 10.1126/science.2448875. View

Larder B, Darby G, Richman D . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989; 243(4899):1731-4. DOI: 10.1126/science.2467383. View

Rooke R, Tremblay M, Soudeyns H, DeStephano L, Yao X, Fanning M . Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. Canadian Zidovudine Multi-Centre Study Group. AIDS. 1989; 3(7):411-5. DOI: 10.1097/00002030-198907000-00001. View

Ho S, Hunt H, Horton R, Pullen J, Pease L . Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989; 77(1):51-9. DOI: 10.1016/0378-1119(89)90358-2. View

10.

Yarchoan R, Perno C, Thomas R, Klecker R, Allain J, Wills R . Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1988; 1(8577):76-81. DOI: 10.1016/s0140-6736(88)90283-8. View

11.

Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

12.

Fischl M, Richman D, GRIECO M, Gottlieb M, Volberding P, Laskin O . The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987; 317(4):185-91. DOI: 10.1056/NEJM198707233170401. View

13.

Vieira J, Messing J . The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. Gene. 1982; 19(3):259-68. DOI: 10.1016/0378-1119(82)90015-4. View

14.

Larder B, Kellam P, Kemp S . Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 1991; 5(2):137-44. DOI: 10.1097/00002030-199102000-00002. View

15.

Howell R, Fitzgibbon J, Noe M, Ren Z, Gocke D, Schwartzer T . In vivo sequence variation of the human immunodeficiency virus type 1 env gene: evidence for recombination among variants found in a single individual. AIDS Res Hum Retroviruses. 1991; 7(11):869-76. DOI: 10.1089/aid.1991.7.869. View

16.

Moore R, Hidalgo J, Sugland B, Chaisson R . Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991; 324(20):1412-6. DOI: 10.1056/NEJM199105163242006. View

17.

Land S, Terloar G, McPhee D, Birch C, Doherty R, Cooper D . Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J Infect Dis. 1990; 161(2):326-9. DOI: 10.1093/infdis/161.2.326. View

18.

Johnson M, McClure M, Feng D, Gray J, Doolittle R . Computer analysis of retroviral pol genes: assignment of enzymatic functions to specific sequences and homologies with nonviral enzymes. Proc Natl Acad Sci U S A. 1986; 83(20):7648-52. PMC: 386778. DOI: 10.1073/pnas.83.20.7648. View

19.

Larder B, Kemp S . Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989; 246(4934):1155-8. DOI: 10.1126/science.2479983. View

20.

Fischl M, Richman D, Causey D, GRIECO M, Bryson Y, Mildvan D . Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group. JAMA. 1989; 262(17):2405-10. View